FDA Clears J&J's Abiraterone Acetate for Prostate Cancer -Bloomberg (JNJ)

by Theo Kratz, Benzinga Staff Writer
April 28, 2011 2:26 PM | 6 seconds read |
Bloomberg reports that the FDA has cleared J&J's JNJ Abiraterone Acetate for prostate cancer.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDAHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!